
Dr. George Yancopoulos, CEO, Regeneron
06/14/22 • 35 min
Previous Episode

Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics
Blood clots of any sort are dangerous. So dangerous in fact, that 1 in 4 people die from blood clots - independent of medical condition, medicines they take, or medical procedures they undergo. Dr. Daniel Bloomfield, the Chief Medical Officer of Anthos Therapeutics, describes their approach to preventing bleeding while avoiding blood clotting.
Next Episode

22-16 Triple-Negative Breast Cancer is the most aggressive of all
Anixa is pioneering a new approach to preventing the truly aggressive triple-negative form of breast cancer. Based on research from Cleveland Clinic, this approach has the potential to treat other breast cancers as well as ovarian cancer. Dr. Amit Kumar is the President & CEO. More information is available at anixa.com.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/biotech-nation-with-dr-moira-gunn-239455/dr-george-yancopoulos-ceo-regeneron-26687948"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to dr. george yancopoulos, ceo, regeneron on goodpods" style="width: 225px" /> </a>
Copy